Disease(s): Acute myeloid leukemia
ETO/AML1 (RUNX1T1/RUNX1) t(8;21)(q22;q22) (M2)
PML/RARα t(15;17)(q22;q21.2) (M3)
MLL (KMT2A) 11q23 rearrangements (M0-M7)
MYH11/CBFβ inv(16)(p13q22), t(16;16) (M4)
EVI1 (MECOM) inv(3)(q21q26) (M1, 2, 4, 6, 7)
Acute myelogenous leukemia (AML), the most common type of leukemia in adults with incidence greatly increasing after age 55-60, constitutes 70% of acute leukemias. AML is characterized by an excess accumulation of immature myeloblasts in bone marrow, leading to a lack of differentiated granulocytes, monocytes, thrombocytes and erythrocytes. Classification of AML into major subgroups from morphological, cytochemical and immunophenotype criteria has resulted in the following FAB subtypes, M0-M71,2: minimally differentiated AML (M0); without maturation (M1); with maturation (M2); acute promyelocytic leukemia, hypergranular (M3) or micro- and hypogranular (M3v); acute myelomonocytic leukemia (M4), including M4Eo with eosinophilia; acute monoblastic leukemia (M5a) and monocytic leukemia (M5b); acute erythroleukemia (M6) and acute megaloblastic leukemia (M7). A more recent WHO classification defines four subgroups: 1) AML with recurrent genetic abnormalities (i.e. as revealed by karyotype or tested for by FISH, above); 2) AML with multilineage dysplasia; 3) therapy-related AML (t-AML) and myelodysplastic syndromes (t-MDS); 4) not otherwise categorized.
Bone Marrow Aspirate (Preferred): 2-5ml, Green-top sodium-heparinized vacutainer
Peripheral Blood: 5-10ml, Green-top sodium-heparinized vacutainer
Storage and Transportation:
Keep at room temperature.
Turn Around Time (TAT):